AEON Biopharma, Inc.
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company developing prabotulinumtoxinA injection (ABP-450) for therapeutic (non-cosmetic) uses as a proposed BOTOX biosimilar in the United States. The company’s strategy is to pursue a Section 351(k) biosimilar Biologics License Application (BLA), using AbbVie’s Botox as the reference product, targeting debilitating medical conditions. ABP-450 is manufactured by Daewoong Pharmaceutical in a cGMP facility that has been approved by the FDA, Health Canada, and the EMA, and the same toxin complex is already approved as a biosimilar in certain international markets. AEON holds exclusive development and distribution rights for certain therapeutic uses across the U.S., Canada, the EU, the UK, and select other territories, positioning it to commercialize if it achieves regulatory approval.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueR&D and regulatory work to develop ABP-450 as a therapeutic botulinum toxin biosimilar via a 351(k) BLA.
Structural analysis and clinical studies (e.g., comparability in cervical dystonia) to support biosimilarity and indications.
Pre-launch planning activities needed to commercialize ABP-450 if approved, including distribution readiness.
Customers
AEON does not currently generate product revenue and is not yet commercializing ABP-450; its end-market customers would be healthcare providers and payors once regulatory approval is obtained. In therapeutic botulinum toxin, demand is driven by neurologists, physiatrists, pain specialists, and other clinicians treating chronic, debilitating conditions where botulinum toxin is an established modality. Payors (commercial insurers and government programs) influence adoption through coverage, step edits, and reimbursement rates, making biosimilar positioning and evidence packages important. If approved, purchasing would typically occur through specialty distributors, group purchasing organizations, and health-system procurement channels, with utilization tied to procedure reimbursement and patient access.
Would use ABP-450 for approved therapeutic indications where botulinum toxin injections are part of care pathways.
Would procure product through formulary processes and buy-and-bill workflows for outpatient and specialty clinics.
Would determine coverage and reimbursement, influencing provider adoption and patient access for biosimilar therapy.
Would handle storage, logistics, and distribution to provider sites for an injectable biologic product.
Strategy
AEON’s core strategy is to develop ABP-450 as a therapeutic BOTOX biosimilar and pursue U.S. approval via a Section 351(k) BLA, using Botox as the reference product. The company expects to invest heavily in early-stage biosimilar requirements such as primary structural analysis and other analytical work, followed by clinical comparability studies (including potential work in cervical dystonia). In parallel, AEON intends to use a product assessment screening process to identify additional therapeutic indications for future development, expanding the potential label and market opportunity. Execution depends on raising additional capital to fund development through regulatory submission and, if approved, commercialization preparation.
Approval requires robust analytical and clinical evidence against the reference product.
More indications can increase addressable market and strengthen commercial rationale.
The company disclosed substantial doubt about going concern without additional financing.
Geography
AEON is U.S.-based and is primarily focused on achieving U.S. market entry for ABP-450 through a 351(k) BLA pathway. The company also holds exclusive development and distribution rights for certain therapeutic uses in Canada, the European Union, the United Kingdom, and certain other international territories, which could expand the addressable commercial footprint over time. Manufacturing for ABP-450 is performed by Daewoong Pharmaceutical in a cGMP facility that has been approved by the FDA, Health Canada, and the EMA, creating operational dependence on an external, non-U.S. manufacturer. Geographic scope matters mainly through regulatory pathways (FDA vs. Health Canada/EMA/UK MHRA), supply chain oversight, and the ability to leverage existing international experience with the same toxin complex.
Risks
AEON is pre-revenue and depends on successful clinical development and regulatory approval of ABP-450; delays or negative outcomes could prevent commercialization entirely. The company disclosed substantial doubt about its ability to continue as a going concern without additional financing, making capital markets access a central business risk. As a biosimilar program, ABP-450 faces scientific and regulatory risk around demonstrating biosimilarity to Botox and translating that into approvable indications, as well as potential competitive responses from the incumbent brand and other toxin products. Operationally, AEON relies on third parties (including Daewoong for manufacturing and CROs/consultants for development), creating supply, quality, and execution risks typical of clinical-stage biotech.
Company stated it lacks sufficient cash to fund 12 months of operations without additional financing.
Exposure: Liquidity and capital markets access
Company disclosed it has never generated revenue from ABP-450 and does not expect revenue until approval.
Exposure: Business model depends on a single late-stage inflection
ABP-450 is manufactured externally; any disruption or compliance issue could delay trials or launch.
Exposure: Supply chain and quality systems
Accounting
Judgemental itemsRemeasurement recognized in earnings can materially change net income/loss without cash impact.
Impact: High volatility in other income/expense and net results
Equity-linked instruments may be marked to fair value, driving non-cash gains/losses.
Impact: Quarterly comparability and valuation-sensitive P&L items
Non-cash compensation expense affects operating loss and per-share metrics.
Impact: Higher reported operating expenses vs. cash operating costs
Similar listed companies
Publicly listed companies with a comparable business focus.
Abeona Therapeutics Inc
ABEO · Pharmaceutical Preparations
ProtoKinetix, Inc.
PKTX · Pharmaceutical Preparations
Xenon Pharmaceuticals Inc.
XENE · Pharmaceutical Preparations
Aibotics, Inc.
AIBT · Medicinal Chemicals & Botanical Products
BeOne Medicines Ltd.
ONC · Pharmaceutical Preparations
Aethlon Medical, Inc
AEMD · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026